Edifoligide Sodium
Title: Edifoligide Sodium
CAS Registry Number: 328538-04-1
CAS Name: DNA d(P-Thio)(C-T-A-G-A-T-T-T-C-C-C-G-C-G) complex with DNA d(P-thio)(G-A-T-C-C-G-C-G-G-G-A-A-A-T)(1:1) hexacosasodium salt
Additional Names: E2F Decoy; E2FD
Manufacturers' Codes: CGT-003
Literature References: Double stranded oligodeoxynucleotide designed to bind and inactivate the cell-cycle transcription factor E2F. Transcription factor decoy used in ex vivo gene suppression therapy to prevent vein graft failure following coronary artery and peripheral artery bypass surgery. Description of sequence and use as decoy: V. J. Dzau et al., WO 9511687; eidem, US 02052333 (1995, 2002). Binding inhibition study in vascular smooth muscle: R. Morishita et al., Proc. Natl. Acad. Sci. USA 92, 5855 (1995); in glomerular mesangial cells: N. Tomita et al., Am. J. Physiol. 275, F278 (1998). Pharmacology: A. Ehsan et al., J. Thorac. Cardiovasc. Surg. 121, 714 (2001). Clinical evaluation in vascular bypass: M. J. Mann et al., Lancet 354, 1493 (1999). Review of mechanism of action: M. J. Mann, Antisense Nucl. Acid Drug Dev. 8, 171-176 (1998).
Therap-Cat: Gene suppression therapy to prevent vein graft atherosclerosis.

Others monographs:
AlbofunginQuinestradiolPipobromanMercufenol Chloride
MeBmtProtocatechuic Acidsym-Dichloromethyl Ether3-Indolylacetone
VIPOil of ChenopodiumFumigatinEverolimus
Ethyl BenzoylacetateTolycaineIsopilosineTrichloroacetic Acid
©2016 DrugLead US FDA&EMEA